乳腺癌患者乳房切除术后重建与不重建的生存与复发率比较
该研究基于约翰霍普金斯医院癌症登记数据,分析1517例2003–2015年因乳腺癌行乳房切除术的女性,比较单纯切除与切除加即刻重建的复发与5年生存。结果显示重建组总体生存有获益趋势但未达统计学显著(HR 0.78,95%CI 0.53–1.13),复发率相似(HR 1.08,95%CI 0.69–1.69),提示重建不增加肿瘤学风险。
要点
- 重建组与单纯切除组乳腺癌复发率相似(HR 1.08,95%CI 0.69–1.69)。
- 重建与总体生存获益相关但未达统计学显著(HR 0.78,95%CI 0.53–1.13)。
- 证据等级为治疗性III级,支持重建不增加肿瘤学风险。
核心结论
- 乳房重建对总体生存或乳腺癌复发率均无负面影响。
研究设计与样本
- 回顾性队列分析约翰霍普金斯医院癌症登记数据,纳入2003–2015年因乳腺癌行乳房切除术的女性1517例。
- 单纯乳房切除504例(33.2%),乳房切除加即刻重建1013例(66.8%),中位随访5.1年。
- 采用Kaplan-Meier曲线比较未调整生存与复发估计,并用Cox比例风险回归模型分析全因死亡时间与癌症复发时间。
主要发现
- 随访期间共132例死亡、100例乳腺癌复发。
- Kaplan-Meier生存估计显示重建组有生存获益。
- 调整临床与社会经济变量后,重建与总体生存获益相关但未达统计学显著(HR 0.78,95%CI 0.53–1.13)。
- 重建组与单纯切除组复发率相似(HR 1.08,95%CI 0.69–1.69)。
临床怎么用
- 在与患者讨论乳房切除术后重建的肿瘤学安全性时,可引用本研究表明重建不增加复发风险且可能不劣于单纯切除的生存。
局限性
- 证据等级为治疗性III级,属回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concerns have been expressed about the oncologic safety of breast reconstruction following mastectomy for breast cancer. This study aimed to evaluate the association of breast reconstruction with breast cancer recurrence, and 5-year survival among breast cancer patients. METHODS: The authors analyzed data from The Johns Hopkins Hospital comprehensive cancer registry, comparing mastectomy-only to postmastectomy breast reconstruction in breast cancer patients to evaluate differences in breast cancer recurrence and 5-year survival. Kaplan-Meier curves were used to compare unadjusted estimates of survival or disease recurrence. Data were modeled through Cox proportional hazards regression, using as outcomes time to death from any cause or time to cancer recurrence. RESULTS: The authors analyzed data on 1517 women who underwent mastectomy for breast cancer at The Johns Hopkins hospital between 2003 and 2015. Of these, 504 (33.2 percent) underwent mastectomy only and 1013 (66.8 percent) underwent mastectomy plus immediate breast reconstruction. Women were followed up for a median of 5.1 years after diagnosis. There were 132 deaths and 100 breast cancer recurrences. A comparison of Kaplan-Meier survival estimates demonstrated a survival benefit among patients undergoing mastectomy plus reconstruction. After adjusting for various clinical and socioeconomic variables, there was still an overall survival benefit associated with breast reconstruction which, however, was not statistically significant (hazard ratio, 0.78; 95 percent CI, 0.53 to 1.13). Patients who underwent reconstruction had a similar rate of recurrence compared to mastectomy-only patients (hazard ratio, 1.08; 95 percent CI, 0.69 to 1.69). CONCLUSION: This study suggests that breast reconstruction does not have a negative impact on either overall survival or breast cancer recurrence rates. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Siotos C, Naska A, Bello RJ, et al. Survival and Disease Recurrence Rates among Breast Cancer Patients following Mastectomy with or without Breast Reconstruction. Plast Reconstr Surg. 2019. PMID: 31348330. doi:10.1097/PRS.0000000000005798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。